X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-09-21 | SGEN | Seagen Inc. | Dansey Roger D | Pres, R, D, CMO | S - Sale | $206.50 | -71 | 116,677 | 0% | -$14,662 | ||||||
2023-09-21 | SGEN | Seagen Inc. | Himes Vaughn B | Chief Technical Officer | S - Sale | $206.50 | -80 | 170,830 | 0% | -$16,520 | ||||||
2023-09-21 | SGEN | Seagen Inc. | Liu Jean I | GC | S - Sale | $206.50 | -64 | 84,398 | 0% | -$13,216 | ||||||
2023-09-21 | SGEN | Seagen Inc. | Romp Charles R | EVP, Commercial U.S. | S - Sale | $206.50 | -45 | 69,111 | 0% | -$9,293 | ||||||
2023-09-21 | SGEN | Seagen Inc. | Simpson Todd E | CFO | S - Sale | $206.50 | -80 | 128,723 | 0% | -$16,520 | ||||||
2023-09-20 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $104.74 | -15,000 | 11,872,969 | 0% | -$1,571,090 | ||||||
2023-09-20 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $17.21 | -8,000 | 902,703 | -1% | -$137,680 | ||||||
| M | 2023-09-20 | DNA | Ginkgo Bioworks Holdings, Inc. | Shetty Reshma P. | See remarks, 10% | S - Sale | $1.80 | -75,300 | 25,727,998 | 0% | -$135,691 | |||||
| M | 2023-09-20 | DNA | Ginkgo Bioworks Holdings, Inc. | Kelly Jason R | See remarks | S - Sale | $1.80 | -200,000 | 6,694,680 | -3% | -$360,400 | |||||
| M | 2023-09-20 | DNA | Ginkgo Bioworks Holdings, Inc. | Canton Barry | 10% | S - Sale | $1.80 | -75,300 | 25,727,998 | 0% | -$135,691 | |||||
2023-09-19 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $8.36 | -8,885 | 7,442,960 | 0% | -$74,278 | ||||||
2023-09-19 | PROK | Prokidney Corp. | Palihapitiya Chamath | 10% | S - Sale | $5.47 | -1,700,000 | 14,573,000 | -10% | -$9,299,000 | ||||||
| M | 2023-09-19 | PKBO | Peak Bio, Inc. | Huh Hoyoung | Dir, 10% | P - Purchase | $0.00 | +80,000 | 8,710,682 | +1% | +$0 | |||||
2023-09-18 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | SVP, HEAD OF RESEARCH | S - Sale | $6.34 | -1,945 | 97,043 | -2% | -$12,331 | ||||||
| D | 2023-09-19 | CABA | Cabaletta Bio, Inc. | Binder Gwendolyn | See Remarks | S - Sale+OE | $17.57 | -11,000 | 20,000 | -35% | -$193,220 | |||||
2023-09-18 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $31.31 | -2,060 | 290,388 | -1% | -$64,500 | ||||||
2023-09-18 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $31.31 | -8,054 | 747,727 | -1% | -$252,175 | ||||||
2023-09-18 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $31.31 | -1,214 | 42,013 | -3% | -$38,011 | ||||||
2023-09-18 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $31.31 | -1,427 | 53,667 | -3% | -$44,680 | ||||||
| D | 2023-09-19 | NMRA | Neumora Therapeutics, Inc. | Burow Kristina | Dir, 10% | P - Purchase | $17.00 | +1,500,000 | 15,524,521 | +11% | +$25,500,000 | |||||
| D | 2023-09-19 | NMRA | Neumora Therapeutics, Inc. | Arch Venture Partners X, LLC | 10% | P - Purchase | $17.00 | +1,500,000 | 29,545,420 | +5% | +$25,500,000 | |||||
| D | 2023-09-19 | NMRA | Neumora Therapeutics, Inc. | Arch Venture Partners X, LLC | 10% | P - Purchase | $17.00 | +1,500,000 | 29,545,420 | +5% | +$25,500,000 | |||||
2023-09-19 | NMRA | Neumora Therapeutics, Inc. | Gosebruch Henry O | Pres, CEO | P - Purchase | $12.62 | +15,000 | 524,793 | +3% | +$189,371 | ||||||
| D | 2023-09-19 | NMRA | Neumora Therapeutics, Inc. | Amgen Inc | 10% | P - Purchase | $17.00 | +1,764,705 | 35,368,653 | +5% | +$29,999,985 | |||||
| D | 2023-09-15 | RXRX | Recursion Pharmaceuticals, Inc. | Virani Shafique | Chief Business Officer | S - Sale+OE | $8.66 | -18,000 | 140,351 | -11% | -$155,880 | |||||
| M | 2023-09-15 | AMAM | Ambrx Biopharma Inc. | Cormorant Asset Management, LP | 10% | P - Purchase | $9.12 | +2,152,738 | 69,465,823 | +3% | +$19,625,601 | |||||
2023-09-15 | DNLI | Denali Therapeutics Inc. | Sato Vicki L | Dir | S - Sale | $23.62 | -1,666 | 129,705 | -1% | -$39,348 | ||||||
2023-09-18 | IOVA | Iovance Biotherapeutics, Inc. | McPeak Merrill A | Dir | P - Purchase | $5.56 | +10,000 | 318,783 | +3% | +$55,600 | ||||||
| DM | 2023-09-15 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale+OE | $31.82 | -7,514 | 96,960 | -7% | -$239,123 | |||||
| D | 2023-09-19 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | S - Sale+OE | $39.10 | -10,000 | 151,911 | -6% | -$390,980 | |||||
| M | 2023-09-15 | PKBO | Peak Bio, Inc. | Lamond Stephen J | See Remarks | P - Purchase | $0.00 | +28,500 | 28,500 | New | +$0 | |||||
2023-09-15 | PKBO | Peak Bio, Inc. | Huh Hoyoung | Dir, 10% | P - Purchase | $0.00 | +25,000 | 8,630,682 | 0% | +$0 | ||||||
2023-09-15 | ADVM | Adverum Biotechnologies, Inc. | Seyedkazemi Setareh | Chief Development Officer | S - Sale | $1.52 | -6,201 | 47,674 | -12% | -$9,429 | ||||||
| D | 2023-09-15 | VYGR | Voyager Therapeutics, Inc. | Carter Todd Alfred | Chief Scientific Officer | S - Sale+OE | $8.16 | -10,500 | 54,360 | -16% | -$85,680 | |||||
2023-09-15 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale | $112.99 | -15,000 | 1,730,236 | -1% | -$1,694,850 | ||||||
2023-09-13 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $109.70 | -15,000 | 11,887,969 | 0% | -$1,645,522 | ||||||
2023-09-15 | IOVA | Iovance Biotherapeutics, Inc. | Rothbaum Wayne P. | Dir | P - Purchase | $5.30 | +5,000,000 | 23,067,333 | +28% | +$26,500,000 | ||||||
2023-09-14 | PALI | Palisade Bio, Inc. | Trenschel Robert J. | Dir | S - Sale | $0.64 | -300 | 0 | -100% | -$192 | ||||||
| M | 2023-09-13 | DNA | Ginkgo Bioworks Holdings, Inc. | Shetty Reshma P. | See remarks, 10% | S - Sale | $2.02 | -75,300 | 25,803,298 | 0% | -$152,068 | |||||
| M | 2023-09-13 | DNA | Ginkgo Bioworks Holdings, Inc. | Canton Barry | 10% | S - Sale | $2.02 | -75,300 | 25,803,298 | 0% | -$152,068 | |||||
| M | 2023-09-13 | DNA | Ginkgo Bioworks Holdings, Inc. | Kelly Jason R | See remarks | S - Sale | $2.02 | -200,000 | 6,894,680 | -3% | -$403,800 | |||||
2023-09-13 | INAB | In8Bio, Inc. | Graff Jeremy R. | Dir | P - Purchase | $0.95 | +2,500 | 2,500 | New | +$2,375 | ||||||
2023-09-14 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | S - Sale | $2.78 | -2,000,000 | 7,971,541 | -20% | -$5,560,000 | ||||||
2023-09-14 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | S - Sale | $2.78 | -2,000,000 | 7,971,541 | -20% | -$5,560,000 | ||||||
| M | 2023-09-13 | PKBO | Peak Bio, Inc. | Huh Hoyoung | Dir, 10% | P - Purchase | $0.00 | +50,000 | 8,605,682 | +1% | +$0 | |||||
| DM | 2023-09-12 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $8.56 | -50,000 | 888,186 | -5% | -$427,950 | |||||
2023-09-13 | PALI | Palisade Bio, Inc. | Finley John David | CEO, CFO, Dir | P - Purchase | $0.66 | +15,000 | 29,171 | +106% | +$9,825 | ||||||
| D | 2023-09-12 | NBIX | Neurocrine Biosciences Inc | Lyons Gary A | Dir | S - Sale+OE | $115.02 | -5,000 | 203,697 | -2% | -$575,120 | |||||
| DM | 2023-09-11 | REPL | Replimune Group, Inc. | Esposito Pamela | Chief Business Officer | S - Sale+OE | $20.01 | -5,658 | 263,436 | -2% | -$113,214 | |||||
2023-09-08 | BCAB | Bioatla, Inc. | McBrinn Sylvia | Dir | P - Purchase | $2.54 | +2,000 | 11,125 | +22% | +$5,080 | ||||||
2023-09-12 | GILD | Gilead Sciences, Inc. | Parsey Merdad | Chief Medical Officer | S - Sale | $76.99 | -1,501 | 70,130 | -2% | -$115,562 | ||||||
2023-09-11 | ALEC | Alector, Inc. | Polaris Venture Management Co. Vi, L.L.C. | 10% | S - Sale | $6.00 | -500,000 | 10,853,817 | -4% | -$3,000,000 | ||||||
2023-09-11 | ALEC | Alector, Inc. | McGuire Terrance | Dir, 10% | S - Sale | $6.00 | -500,000 | 10,948,212 | -4% | -$3,000,000 | ||||||
2023-09-11 | CDTX | Cidara Therapeutics, Inc. | Tari Leslie | CHIEF SCIENTIFIC OFFICER | S - Sale | $0.95 | -18,469 | 277,194 | -6% | -$17,509 | ||||||
2023-09-11 | CDTX | Cidara Therapeutics, Inc. | Sandison Taylor | Chief Medical Officer | S - Sale | $0.95 | -18,793 | 363,757 | -5% | -$17,810 | ||||||
| M | 2023-09-11 | PKBO | Peak Bio, Inc. | Huh Hoyoung | Dir, 10% | P - Purchase | $0.00 | +47,000 | 8,555,682 | +1% | +$0 | |||||
2023-09-11 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $127.23 | -50,000 | 3,398,544 | -1% | -$6,361,680 | ||||||
2023-09-11 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $127.23 | -50,000 | 3,398,544 | -1% | -$6,361,680 | ||||||
| AM | 2023-08-29 | PKBO | Peak Bio, Inc. | Huh Hoyoung | Dir, 10% | P - Purchase | $0.00 | +0 | 8,508,682 | 0% | +$0 | |||||
2023-09-08 | XFOR | X4 Pharmaceuticals, Inc | Dibiase Mary | COO | S - Sale | $1.25 | -2,642 | 147,894 | -2% | -$3,300 | ||||||
| D | 2023-09-08 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $107.22 | -557 | 7,215 | -7% | -$59,722 | |||||
2023-09-06 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $107.61 | -15,000 | 14,868,952 | 0% | -$1,614,094 | ||||||
| D | 2023-09-07 | SGEN | Seagen Inc. | Himes Vaughn B | Chief Technical Officer | S - Sale+OE | $205.76 | -8,785 | 170,910 | -5% | -$1,807,602 | |||||
| D | 2023-09-06 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $8.81 | -58,765 | 871,291 | -6% | -$517,442 | |||||
| M | 2023-09-06 | DNA | Ginkgo Bioworks Holdings, Inc. | Kelly Jason R | See remarks | S - Sale | $2.18 | -200,000 | 7,094,680 | -3% | -$436,200 | |||||
| M | 2023-09-06 | DNA | Ginkgo Bioworks Holdings, Inc. | Shetty Reshma P. | See remarks, 10% | S - Sale | $2.18 | -75,300 | 25,878,598 | 0% | -$164,116 | |||||
| M | 2023-09-06 | DNA | Ginkgo Bioworks Holdings, Inc. | Canton Barry | 10% | S - Sale | $2.18 | -75,300 | 25,878,598 | 0% | -$164,116 | |||||
2023-09-05 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $8.79 | -8,885 | 7,451,845 | 0% | -$78,136 | ||||||
2023-09-06 | EDIT | Editas Medicine, Inc. | Eaton Bruce | EVP, CBO, CTO | S - Sale | $8.82 | -103 | 75,728 | 0% | -$908 | ||||||
| D | 2023-09-06 | MRNA | Moderna, Inc. | Garay Arpa | Chief Commercial Officer | S - Sale+OE | $108.40 | -574 | 3,113 | -16% | -$62,219 | |||||
| D | 2023-09-01 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $35.05 | -40,000 | 720,357 | -5% | -$1,401,973 | |||||
| D | 2023-09-01 | RVMD | Revolution Medicines, Inc. | Weber Barbara | Dir | S - Sale+OE | $35.07 | -15,000 | 15,825 | -49% | -$526,001 | |||||
| D | 2023-09-01 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $35.05 | -20,000 | 55,094 | -27% | -$701,092 | |||||
2023-09-05 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $5.19 | -5,647 | 5,575,823 | 0% | -$29,333 | ||||||
2023-09-05 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $5.19 | -6,214 | 177,935 | -3% | -$32,277 | ||||||
2023-09-05 | ALEC | Alector, Inc. | Romano Gary | Chief Medical Officer | S - Sale | $5.19 | -2,771 | 99,349 | -3% | -$14,393 | ||||||
2023-09-05 | ALEC | Alector, Inc. | Grasso Marc | CFO | S - Sale | $5.19 | -1,114 | 32,247 | -3% | -$5,786 | ||||||
| D | 2023-09-05 | BIIB | Biogen Inc. | Singhal Priya | Head of Development | S - Sale+OE | $269.43 | -431 | 3,354 | -11% | -$116,124 | |||||
| D | 2023-09-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $52.82 | -3,000 | 167,935 | -2% | -$158,447 | |||||
2023-09-05 | DNA | Ginkgo Bioworks Holdings, Inc. | Henry Christian O | Dir | S - Sale | $2.23 | -4,499 | 1,243,377 | 0% | -$10,033 | ||||||
| D | 2023-09-05 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $2.24 | -41,417 | 543,585 | -7% | -$92,567 | |||||
2023-09-05 | BLUE | Bluebird Bio, Inc. | Klima Thomas J | See Remarks | S - Sale | $3.79 | -922 | 132,127 | -1% | -$3,493 | ||||||
| D | 2023-09-01 | NBIX | Neurocrine Biosciences Inc | Lyons Gary A | Dir | S - Sale+OE | $110.06 | -5,000 | 203,697 | -2% | -$550,316 | |||||
2023-09-01 | NBIX | Neurocrine Biosciences Inc | Cooke Julie | CHRO | S - Sale | $110.93 | -824 | 17,263 | -5% | -$91,406 | ||||||
| D | 2023-09-05 | MRNA | Moderna, Inc. | Klinger Shannon Thyme | GC | S - Sale+OE | $111.44 | -115 | 6,634 | -2% | -$12,815 | |||||
| D | 2023-09-05 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $111.44 | -320 | 1,745,236 | 0% | -$35,660 | |||||
2023-09-01 | BCLI | Brainstorm Cell Therapeutics Inc. | Lindborg Stacy | Co-CEO | P - Purchase | $1.77 | +11,500 | 181,500 | +7% | +$20,402 | ||||||
2023-08-30 | EXEL | Exelixis, Inc. | Aftab Dana | CSO, EVP Disc, Trans Research | S - Sale | $22.47 | -4,600 | 405,778 | -1% | -$103,362 | ||||||
2023-09-01 | ADAP | Adaptimmune Therapeutics Plc | Rawcliffe Adrian | CEO | S - Sale | $0.78 | -2,403 | 3,449 | -41% | -$1,874 | ||||||
2023-08-30 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $115.46 | -15,000 | 14,883,952 | 0% | -$1,731,951 | ||||||
2023-08-31 | SGEN | Seagen Inc. | Dansey Roger D | Pres, R, D, CMO | S - Sale | $206.97 | -4,029 | 111,768 | -3% | -$833,866 | ||||||
2023-08-31 | SGEN | Seagen Inc. | Himes Vaughn B | Chief Technical Officer | S - Sale | $206.97 | -1,795 | 170,910 | -1% | -$371,504 | ||||||
2023-08-31 | SGEN | Seagen Inc. | Liu Jean I | GC | S - Sale | $206.97 | -1,893 | 84,462 | -2% | -$391,786 | ||||||
2023-08-31 | SGEN | Seagen Inc. | Romp Charles R | EVP, Commercial U.S. | S - Sale | $206.97 | -555 | 69,156 | -1% | -$114,866 | ||||||
2023-08-31 | SGEN | Seagen Inc. | Simpson Todd E | CFO | S - Sale | $206.97 | -2,122 | 128,803 | -2% | -$439,182 | ||||||
| M | 2023-08-30 | DNA | Ginkgo Bioworks Holdings, Inc. | Canton Barry | 10% | S - Sale | $2.26 | -75,300 | 25,953,898 | 0% | -$169,802 | |||||
| M | 2023-08-30 | DNA | Ginkgo Bioworks Holdings, Inc. | Kelly Jason R | See remarks | S - Sale | $2.25 | -200,000 | 7,294,680 | -3% | -$450,700 | |||||
| M | 2023-08-30 | DNA | Ginkgo Bioworks Holdings, Inc. | Shetty Reshma P. | See remarks, 10% | S - Sale | $2.26 | -75,300 | 25,953,898 | 0% | -$169,802 | |||||
2023-08-30 | NBIX | Neurocrine Biosciences Inc | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $107.60 | -2,733 | 3,460 | -44% | -$294,058 | ||||||
| D | 2023-08-31 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale+OE | $34.05 | -10,000 | 99,474 | -9% | -$340,458 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |